Condition: Colorectal Neoplasms · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Columbia University Medical Center Herbert Irving Pavilion | New York, New York, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Recruiting |
| NEXT Oncology | Fairfax, Virginia, United States | Recruiting |
| Severance Hospital Yonsei University Health System | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
| Hosp Univ Vall D Hebron | Barcelona, Spain | Recruiting |
| Hosp Univ Fund Jimenez Diaz | Madrid, Spain | Recruiting |
| Hosp. Univ. 12 de Octubre | Madrid, Spain | Recruiting |
| Hosp Univ Hm Sanchinarro | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07107230